- Home
- TLPH vs SCYX Comparison
TLPH vs SCYX Comparison
Compare TLPH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | SCYX |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 32.6M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TLPH | SCYX |
|---|---|---|
| Price | $0.92 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 227.4K | ★ 328.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | $257,000.00 |
| Revenue This Year | N/A | $170.77 |
| Revenue Next Year | N/A | $286.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.57 |
| 52 Week High | $1.57 | $1.29 |
Technical Indicators
Market Signals| Indicator | TLPH | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 50.14 |
| Support Level | $0.86 | $0.69 |
| Resistance Level | $1.05 | $0.88 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 62.43 | 31.71 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.